Applications of coumarin compounds in preparing HIV-latency-resisting treatment medicine

A technology for coumarins and therapeutic drugs, which is applied in the field of medicine to achieve the effects of low cytotoxicity and accelerated clearance

Inactive Publication Date: 2016-06-29
FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, so far, there has been no report about t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of coumarin compounds in preparing HIV-latency-resisting treatment medicine
  • Applications of coumarin compounds in preparing HIV-latency-resisting treatment medicine
  • Applications of coumarin compounds in preparing HIV-latency-resisting treatment medicine

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0042] Example 1. Effect of the concentration of Hymecromone and Scoparone compounds on HIV latency-induced activation efficiency

[0043] C11 cells were seeded in a 96-well plate at 2×10E4 cells per well, and 100ul 1640 medium (Gibco) containing 10% FBS (Gibco) was added to each well. After 24 hours, different concentrations of Hymecromone and Scoparone were added to make the final The concentrations were 0 μM, 300 μM, 400 μM, 500 μM, and 600 μM, respectively. There were at least 3 replicate wells for each concentration, and each experiment was repeated 3 times. After 72 hours of drug treatment, the GFP expression in the cells was observed under a fluorescence microscope, and the cells were collected for flow cytometry detection to analyze the proportion of fluorescent cells;

[0044] The results showed that with the increase of the concentrations of Hymecromone and Scoparone compounds, the number of cells expressing green fluorescence in the cell model increased; the proport...

Example Embodiment

[0045] Example 2. The effect of action time of Hymecromone and Scoparone compounds on HIV latency-induced activation efficiency

[0046] 2×10E4 C11 cells per well were seeded in a 96-well plate, and 100ul 1640 medium (Gibco) containing 10% FBS (Gibco) was added to each well. After 24 hours, Hymecromone and Scoparone with a final concentration of 500 μM were added. After 24h, 48h, 72h, and 96h of cell treatment, the expression of GFP in cells was observed under a fluorescence microscope, and cells were collected for flow cytometry detection, and the proportion of fluorescent cells was analyzed. Each experiment was repeated 3 times, and the kinetics of induced activation was analyzed and compared;

[0047] The results showed that when Hymecromone and Scoparone treated the HIV latent infection cell model respectively, the number of green fluorescence positive cells gradually increased with time. Hymecromone treated the HIV latent infection cell model for 72h. The proportion of g...

Example Embodiment

[0048] Example 3. Toxic effects of Hymecromone and Scoparone on cells

[0049] 2×10E4 normal human peripheral blood mononuclear cells (PBMC) per well were planted in 96-well plates, and 100ul DMEM medium (Gibco) containing 10% FBS (Gibco) was added to each well. After 24 hours, different concentrations were added respectively. Hymecromone and Scoparone to make final concentrations of 0 μM, 100 μM, 500 μM, 1000 μM, 2500 μM, and 5000 μM, respectively, with at least 3 replicate wells for each concentration, and each experiment was repeated 3 times. After 72 hours of drug treatment, cells were added to each well. MTT reagent (0.5 mg / mL) (purchased from SIGMA), shake for 1 h, and measure the OD value at 570 nm on a microplate reader;

[0050]The results showed that the half-toxic concentrations of Hymecromone and Scoparone on human normal cells were CC50=2100μM and CC50=2400μM, respectively. The results showed that Hymecromone and Scoparone had lower toxicity at the activation conc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and in particular relates to applications of coumarin compounds in preparing an HIV-latency-resisting treatment medicine. The experiment shows that the coumarin compounds provided by the invention have the effect of inducing cells with HIV latency to be activated, and have lower toxicity on cells compared with similar compounds, especially, after the compounds are combined with the medicines capable of resisting the retroviruses, the activated cells with latent infection can be killed, so that the latent viral reservoir can be rapidly cleared, and the coumarin compounds can provide a novel treatment medicine path for the radical cure of AIDS.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of coumarin compounds in the preparation of anti-HIV latent therapeutic drugs. Background technique [0002] Acquired Immunodeficiency Syndrome (AIDS) is an infectious disease caused by HIV infection that seriously endangers people's life and health. According to WHO statistics, there are more than 40 million AIDS patients in the world, with 5 million new patients and 3 million deaths each year. At present, the clinical treatment of AIDS is mainly Highly active antiretroviral therapy (HAART), which not only effectively controls HIV replication, but also can rebuild the immune function of AIDS patients, opening the door of hope for the treatment of AIDS. People once hoped that HAART could completely eliminate HIV in the body, thereby achieving the goal of completely curing AIDS, but subsequent research practice has proved that although HAART can suppress virus ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/37A61K31/7048A61P31/18
Inventor 朱焕章曲喜英曾汉献刘琳
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap